Fundraising Fox
Akonni Biosystems
Fredrick, US · Delaware corporation
Find your way into Akonni Biosystems
Sign up to see every warm intro you have to Akonni Biosystems
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Akonni Biosystems team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Akonni Biosystems is a molecular diagnostics company that develops, manufactures, and sells integrated diagnostic systems along with nucleic acid sample preparation products. Its offerings include the TruTip DNA/RNA purification kits and tips, TruPrepR, and TruDiagnosis product lines, produced at its roughly 20,000 square foot facility in Frederick, Maryland.
Founders & leadership
CD
Charles DaitchFounder
JD
Jon DavisPresident & CEOJon Davis brings over 30 years of general management and 20 years of product development experience in biosensor technology across chemistry, biology, engineering, and related disciplines. He has led multidisciplinary teams at diagnostic companies including 447 Corp and Akonni, where he serves as President with responsibility for strategy, product management, and operations.
GR
George RudyExecutive
DC
Darrell ChandlerNamed on SEC filing
Board
TM
Tom McMahonBoard director
CP
Chuck ParrishBoard director
MF
Michael FarmerBoard director
DK
David KeysBoard director
TH
Thomas HigginsBoard director
Reported raises · per SEC filings
Form D private placements$22M disclosed across 9 rounds · 2012–2019
▶$1.8MraisedJun 2019 · 21 investors · BiotechnologyRule 506(b)
▶$1.8MraisedJun 2019 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence FirestoneExecutive Officer
- Mary PittmanDirector
- Dr. Myun HanDirector
- Jon DavisExecutive Officer
- Thomas HigginsDirector
- David KeysDirector
- Darrell ChandlerExecutive Officer
- Tom McMahonDirector
- Chuck ParrishDirector
- Charles DaitchExecutive Officer, Director
- Michael FarmerDirector
- Offering amount
- $4.6M
- Amount sold
- $1.8M
- Minimum investment
- $25K
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedAug 2018 · 16 investors · BiotechnologyRule 506(b)
▶$1.1MraisedAug 2018 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian MorraDirector
- Charles DaitchExecutive Officer, Director
- Michael FarmerDirector
- Dr. Jialu WuDirector
- Mary PittmanDirector
- David KeysDirector
- Chuck ParrishDirector
- Thomas HigginsDirector
- Lawrence FirestoneExecutive Officer
- Tom McMahonDirector
- Jon DavisExecutive Officer
- Darrell ChandlerExecutive Officer
- Offering amount
- $7M
- Amount sold
- $1.1M
- Minimum investment
- $25K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.5MraisedFeb 2018 · 1 investors · BiotechnologyRule 506(b)
▶$7.5MraisedFeb 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles DaitchExecutive Officer, Director
- Brian MorraDirector
- Jon DavisExecutive Officer
- Darrell ChandlerExecutive Officer
- Mark WoodDirector
- Tom McMahonDirector
- Mary PittmanDirector
- Thomas HigginsDirector
- Chuck ParrishDirector
- Michael FarmerDirector
- David KeysDirector
- Offering amount
- $7.5M
- Amount sold
- $7.5M
- Minimum investment
- $25K
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedJan 2018 · 26 investors · BiotechnologyRule 506(b)
▶$2.4MraisedJan 2018 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas HigginsDirector
- Mary PittmanDirector
- Jon DavisExecutive Officer
- Michael FarmerDirector
- Darrell ChandlerExecutive Officer
- Brian MorraDirector
- Chuck ParrishDirector
- Charles DaitchExecutive Officer, Director
- Tom McMahonDirector
- David KeysDirector
- Offering amount
- $2.4M
- Amount sold
- $2.4M
- Minimum investment
- $25K
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedSep 2017 · 18 investors · BiotechnologyRule 506(b)
▶$2.3MraisedSep 2017 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles DaitchExecutive Officer, Director
- Thomas HigginsDirector
- Tom McMahonDirector
- Michael MurphyExecutive Officer
- Brian MorraDirector
- Chuck ParrishDirector
- Michael FarmerDirector
- Jon DavisExecutive Officer
- Mary PitmanDirector
- David KeysDirector
- Darrell ChandlerExecutive Officer
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- Minimum investment
- $25K
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedMar 2017 · 33 investors · BiotechnologyRule 506(b)
▶$4MraisedMar 2017 · 33 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jon DavisExecutive Officer
- Tom McMahonDirector
- Charles DaitchExecutive Officer, Director
- Chuck ParrishDirector
- Thomas HigginsDirector
- Michael FarmerDirector
- Mary PitmanDirector
- Michael MurphyExecutive Officer
- David KeysDirector
- Brian MorraDirector
- Darrell ChandlerExecutive Officer
- Offering amount
- $6M
- Amount sold
- $4M
- Minimum investment
- $25K
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedMay 2016 · 4 investors · BiotechnologyRule 506(b)
▶$1.3MraisedMay 2016 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles DaitchExecutive Officer, Director
- Tom McMahonDirector
- Brian MorraDirector
- Chuck ParrishDirector
- Michael FarmerDirector
- David KeysDirector
- Mary PittmanDirector
- Thomas HigginsExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.3M
- Minimum investment
- $25K
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$619KraisedDec 2015 · 7 investors · BiotechnologyRule 506(b)
▶$619KraisedDec 2015 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tom McMahonDirector
- Chuck ParrishDirector
- Jon DavisExecutive Officer
- Charles DaitchExecutive Officer, Director
- Darrell ChandlerExecutive Officer
- Michael FarmerDirector
- David KeysDirector
- Thomas HigginsDirector
- Offering amount
- $3M
- Amount sold
- $619K
- Minimum investment
- $25K
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 24 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $299.6K |
| Food and Drug Administration (FDA)Food and Drug Administration | Phase I | 2021 | $168.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $149K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $1.2M |
| National Science Foundation | Phase II | 2012 | $498.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $280.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $300K |
| National Science Foundation | Phase I | 2011 | $150K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $424.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2009 | $3M |
| Department of Energy | Phase II | 2007 | $750K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $294.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $278.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $1.1M |
| National Science Foundation | Phase I | 2006 | $100K |
| Department of Energy | Phase I | 2006 | $99.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Akonni Biosystems do?
- Akonni Biosystems is a molecular diagnostics company that develops, manufactures, and sells integrated diagnostic systems along with nucleic acid sample preparation products. Its offerings include the TruTip DNA/RNA purification kits and tips, TruPrepR, and TruDiagnosis product lines, produced at its roughly 20,000 square foot facility in Frederick, Maryland.
- Who founded Akonni Biosystems?
- Akonni Biosystems was founded by Charles Daitch.
- How much funding has Akonni Biosystems raised?
- Akonni Biosystems has disclosed $22M raised across 9 rounds.
- Where is Akonni Biosystems headquartered?
- Akonni Biosystems is headquartered in Fredrick, US.